论文部分内容阅读
急性冠脉综合征(acute coronary syndrome,ACS)是导致我国冠心病患者死亡的主要原因,ACS的诊断主要依据临床症状、心电图和血液中的生物标志物,早期诊断ACS可提高患者的生存率。生物标志物在ACS的诊断、治疗及预后方面都起着重要作用。目前心肌肌钙蛋白已经作为急性心肌梗死(acute myocardial infarction,AMI)诊断的首选生物学指标,其特异性和敏感性均较高,但临床上需要一个可以快速诊断或者排除AMI同时指导AMI治疗及判断预后的“理想生物标志物”。本文作者阐述目前ACS生物标志物的研究进展,寻找那些可能成为ACS诊断、治疗及预后的新的生物学指标。
Acute coronary syndrome (ACS) is the leading cause of death in patients with coronary heart disease in China. The diagnosis of ACS is mainly based on clinical symptoms, ECG and blood biomarkers. Early diagnosis of ACS can improve the survival rate of patients. Biomarkers play an important role in the diagnosis, treatment and prognosis of ACS. At present, cardiac troponin has been used as the biological indicator of choice in the diagnosis of acute myocardial infarction (AMI), and its specificity and sensitivity are high. However, there is a clinical need for a clinical diagnosis and AMI that can be quickly diagnosed or excluded, To determine the prognosis “ideal biomarker ”. The authors describe the current advances in the use of biomarkers for ACS and look for new biological indicators that may be useful in the diagnosis, treatment and prognosis of ACS.